Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA in Chinese Subjects With Relapsed or Refractory Multiple Myeloma

Next Previous
Trial Profile

A Phase 2, Open-Label Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA in Chinese Subjects With Relapsed or Refractory Multiple Myeloma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciltacabtagene autoleucel (Primary)
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms CARTIFAN-1
  • Sponsors Nanjing Legend Biotech

Most Recent Events

  • 27 Aug 2024 According to a GenScript Biotech Corp media release, based on the data from this study, Ciltacabtagene-autoleucel drug has received approval in the China by National Medical Products Administration (NMPA) for the treatment multiple myeloma.
  • 23 May 2024 According to a Legend Biotech media release, data from this study will be presented at the 2024 European Hematology Association's (EHA) Hybrid Congress.
  • 02 Nov 2023 According to a Legend Biotech media release, data from this study will be presented at the 65th American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top